Metabolomics of Oxalobacter Formigenes to Characterize Intestinal Oxalate Secretion
Casey A. Chamberlain, Marguerite Hatch, Timothy J. Garrett University of Florida
Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704
Casey Chamberlain (Presenter) University of Florida
Presenter Bio: Casey Chamberlain is a 4th-year graduate student at the University of Florida College of Medicine. His work in the laboratory of Dr. Timothy Garrett is focused on using LC-MS-based metabolomics approaches to understand the biochemical relationship between the intestinal microbiome and the human host as it relates to diseases of oxalic acid, such as kidney stone disease and primary hyperoxaluria.
Relevant Financial Disclosures
(within past 24 months)
No relevant financial relationship(s) to disclose.
Abstract
This presentation summarizes the first characterization of the metabolome and lipidome of a class of bacteria in the intestinal microbiome believed to reduce the risk of kidney stone disease by degrading oxalate, a major component of most kidney stones. Using UHPLC-HRMS-based global and targeted metabolomics, we performed a comparative analysis of five species of oxalate-degrading bacteria, specifically focusing on compounds exclusive to Oxalobacter formigenes, which secretes a unique, unidentified bioactive compound that removes oxalate from the bloodstream. This study seeks to identify this secreted compound for future evaluation as a therapeutic or preventative treatment for kidney stones.
= Discovery stage. (17.55%, 2019 US)
= Translation stage. (42.72%, 2019 US)
= Clinically available. (39.74%, 2019 US)
